---
title: Research Vision
subtitle: Bridging Cellular Complexity and Molecular Precision
summary: Developing integrated single-molecule platforms to study protein-DNA competition under physiologically relevant conditions
date: 2025-10-31
keywords:
  - Single-molecule biophysics
  - Nanofluidic confinement
  - Chromatin regulation
  - p53-histone competition
  - Molecular crowding
---

## üéØ Research Philosophy: The Integration Challenge

Biology operates at the intersection of **complexity** and **precision**. Cellular processes occur under extreme molecular crowding (300-400 mg/mL) and spatial confinement, yet traditional biochemistry studies proteins in dilute conditions (1-10 mg/mL) that fail to capture this reality.

**My Vision:** Build integrated experimental platforms that recreate physiological constraints while maintaining single-molecule resolution.

---

## üî¨ Core Innovation: Nano-Channel Platform

{{< figure src="/images/research/integration-concept.png" alt="Research Integration Concept" caption="Bridging cellular reality with molecular precision through nanofluidic confinement" >}}

### The Technical Breakthrough

Our platform uniquely combines three critical elements:

1. **Graduated Nanofluidic Channels (50 nm - 2 ¬µm)**
   - Systematically control spatial confinement
   - Mimic nuclear compartmentalization
   
2. **Multi-Reservoir Microfluidics**
   - Precisely tune molecular crowding (0-300 mg/mL)
   - Real-time buffer exchange
   - Multi-protein competition assays

3. **Single-Molecule Fluorescence (TIRF)**
   - Three-color simultaneous imaging
   - Real-time binding dynamics
   - Sub-second temporal resolution

**Key Advantage:** First platform to independently control AND systematically vary both spatial confinement and molecular crowding.

---

## üéØ Flagship Project: p53-Chromatin Competition

{{< figure src="/images/research/technical-platform.png" alt="Integrated Platform" caption="Multi-scale experimental system combining TIRF microscopy with nano/microfluidics" >}}

### The Central Question

**How does the tumor suppressor p53 access DNA binding sites when chromatin is compacted by histones?**

This competition determines whether p53 can activate its target genes to prevent cancer. Understanding the physical mechanisms is crucial for developing drugs that enhance p53 function.

### Why Current Methods Fall Short

| Limitation | Impact | Our Solution |
|------------|---------|-------------|
| **Bulk biochemistry** | Averages over millions of molecules | Single-molecule resolution |
| **Dilute conditions** | 10-100√ó less crowded than cells | Tunable crowding (0-300 mg/mL) |
| **No spatial control** | Cannot separate crowding vs. confinement effects | Graduated nanochannels (50 nm - 2 ¬µm) |
| **Static endpoints** | Misses dynamic competition | Real-time kinetics tracking |

### Research Strategy

**Stage 1-2: From Components to Competition** (Years 1-3)
- Characterize individual protein-DNA interactions under varying crowding
- Measure p53-histone competition on native genomic sequences
- Quantify how crowding and confinement shift binding equilibrium

**Stage 3: Therapeutic Applications** (Years 4-6)
- Screen compounds that modulate chromatin accessibility
- Identify molecules enhancing p53 binding to target genes
- Develop predictive framework for drug efficacy across cancer types

---

## üí° Expected Impact

### üî¨ Fundamental Science

**New Physical Principles**
- Quantitative relationships between crowding, confinement, and protein competition
- Molecular rules governing transcription factor access under physiological constraints
- General framework applicable to any protein-DNA system

### üõ†Ô∏è Methodological Advances

**Paradigm for Multi-Protein Studies**
- Technology platform for studying competitive binding
- Broadly applicable to chromatin biology and transcriptional regulation
- Enables previously impossible systematic parameter studies

### üíä Translational Medicine

**Precision Cancer Therapeutics**
- Drug screening for chromatin accessibility modulators
- Predictive models for compound efficacy across p53 mutational backgrounds
- Direct relevance: p53 mutations in >50% of human cancers

---

## üåâ The Bigger Picture

This research exemplifies **quantitative biology**‚Äîusing physics-based approaches to answer fundamental biological questions. The platform I'm developing will enable systematic investigation of how physical constraints shape molecular interactions in living systems.

> *"The goal is not just to study p53 and histones, but to establish general principles for how proteins compete under cellular conditions‚Äîprinciples that will inform our understanding of gene regulation, epigenetics, and therapeutic intervention."*

---

## üîó Learn More

- **[Research Trajectory](/research/trajectory)**: How my interdisciplinary background led to this vision
- **[Publications](/publications)**: See my previous work on DNA-protein interactions
- **[Full Research Proposal](/)**: Download detailed proposal (PDF)

---

<div class="alert alert-info">
<h4>ü§ù Collaboration Opportunities</h4>

I'm actively seeking collaborations in:
- **Biochemistry**: Protein purification and characterization
- **Computational Biology**: Molecular dynamics simulations of crowded systems
- **Cancer Biology**: Validation in cellular models
- **Drug Discovery**: Compound library screening

**Contact:** [sun_yuting@icloud.com](mailto:sun_yuting@icloud.com)
</div>
